Serum amyloid A, C-reactive protein, and retinal microvascular changes in hypertensive diabetic and nondiabetic individuals: An Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) substudy

Diabetes Care

Volumn 32, Issue 6, 2009, Pages 1098-1100

  Stettler, Christoph ^a,b   Witt, Nicholas ^b   Tapp, Robyn J ^b,c   Thom, Simon ^b   Allemann, Sabin ^a   Tillin, Therese ^b   Stanton, Alice ^d   O'Brien, Eoin ^e   Poulter, Neil ^b   Gallimore, J Ruth ^f   Hughes, Alun D ^b   Chaturvedi, Nish ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c MONASH UNIVERSITY   (Australia)

^d ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^e UNIVERSITY COLLEGE DUBLIN   (Ireland)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID A PROTEIN; C REACTIVE PROTEIN;

ADULT; AGED; ARTERIOLE; ARTICLE; BLOOD VESSEL DIAMETER; BODY MASS; CONTROLLED STUDY; DIABETIC RETINOPATHY; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; HYPERTENSION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RETINA BLOOD VESSEL; SYSTOLIC BLOOD PRESSURE;

C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; DIABETES COMPLICATIONS; EUROPE; GREAT BRITAIN; HUMANS; HYPERTENSION; MICROCIRCULATION; RETINAL VESSELS; SERUM AMYLOID A PROTEIN;

EID: 66549115458     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc08-2137     Document Type: Article

References (15)

1. Ikram MK, de Jong FJ, Vingerling JR, Witteman JC, Hofman A, Breteler MM, de Jong PT. Are retinal arteriolar or venular diameters associated with markers for cardiovascular disorders? The Rotterdam Study. Invest Ophthalmol Vis Sci 2004;45:2129-2134 (Pubitemid 38902580)
2. Klein R, Klein BE, Knudtson MD, Wong TY, Tsai MY. Are inflammatory factors related to retinal vessel caliber? The Beaver Dam Eye Study. Arch Ophthalmol 2006;124:87-94 (Pubitemid 43063893)
3. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115-126
4. Malle E, De Beer FC. Human serum amyloid A (SAA) protein: a prominent acutephase reactant for clinical practice. Eur J Clin Invest 1996;26:427-435 (Pubitemid 26226404)
5. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial: ASCOT investigators. J Hypertens 2001;19:1139-1147 (Pubitemid 32493649)
6. Stanton A, Fitzgerald D, Hughes A, Mayet J, O'Brien E, Poulter N, Sever P, Shields D, Thom S. An intensive phenotyping study to enable the future examination of genetic influences on hypertension-associated cardiovascular disease. J Hum Hypertens 2001;15(Suppl. 1):S13-S18 (Pubitemid 32904101)
7. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOTLLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-1158 (Pubitemid 36398384)
8. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906 (Pubitemid 41265663)
9. Witt N, Wong TY, Hughes AD, Chaturvedi N, Klein BE, Evans R, McNamara M, Thom SA, Klein R. Abnormalities of retinal microvascular structure and risk of mortality from ischemic heart disease and stroke. Hypertension 2006;47:975-981 (Pubitemid 44297571)
10. Ledue TB, Weiner DL, Sipe JD, Poulin SE, Collins MF, Rifai N. Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. Ann Clin Biochem 1998;35:745-753 (Pubitemid 28523808)
11. McAdam KP, Elin RJ, Sipe JD, Wolff SM. Changes in human serum amyloid A and C-reactive protein after etiocholanolone-induced inflammation. J Clin Invest 1978;61:390-394 (Pubitemid 8280409)
12. Raynes JG, Cooper EH. Comparison of serum amyloid A protein and C-reactive protein concentrations in cancer and nonmalignant disease. J Clin Pathol 1983;36:798-803
13. Katayama T, Nakashima H, Takagi C, Honda Y, Suzuki S, Iwasaki Y, Yamamoto T, Yoshioka M, Yano K. Serum amyloid a protein as a predictor of cardiac rupture in acute myocardial infarction patients following primary coronary angioplasty. Circ J 2006;70:530-535
14. Katayama T, Nakashima H, Takagi C, Honda Y, Suzuki S, Iwasaki Y, Yano K. Prognostic value of serum amyloid A protein in patients with acute myocardial infarction. Circ J 2005;69:1186-1191 (Pubitemid 41382936)
15. Kokubun M, Imafuku Y, Okada M, Ohguchi Y, Ashikawa T, Yamada T, Yoshida H. Serum amyloid A (SAA) concentration varies among rheumatoid arthritis patients estimated by SAA/CRP ratio. Clin Chim Acta 2005;360:97-102 (Pubitemid 41225398)